CJC-1295 Global Regulatory Status: FDA, EMA, and Worldwide Classification

What Is CJC-1295 and Why Does It Lack Approval?

CJC-1295 is a synthetic 30-amino-acid peptide analog of growth hormone-releasing hormone (GHRH), specifically a modified version of GRF(1-29). The compound was developed by ConjuChem Biotechnologies (later ConjuChem LLC) to extend the biological half-life of native GHRH, which degrades in plasma within minutes. The drug affinity complex (DAC) technology covalently attaches a reactive chemical group that binds to circulating albumin after subcutaneous injection, extending the peptide's functional half-life from roughly 30 minutes to 6-8 days 1.

ConjuChem conducted early-phase trials in healthy adults and in populations with growth hormone deficiency. The only published controlled study, a Phase II ascending-dose trial by Teichman et al. (2006), enrolled 21 healthy males aged 21-40 and demonstrated dose-dependent increases in GH and IGF-1 levels at subcutaneous doses of 30, 60, and 90 mcg/kg 1. However, ConjuChem ceased clinical development before filing any New Drug Application (NDA) or Biologics License Application (BLA) with the FDA. A death reported during clinical trials contributed to the suspension of the manufacturer-sponsored development program. No other pharmaceutical company has since pursued regulatory approval for CJC-1295 in any jurisdiction.

United States: FDA Regulatory Position

CJC-1295 has no FDA-approved indication, label, or prescribing information. It does not appear in the Drugs@FDA database, which catalogs all FDA-approved drug products. No Investigational New Drug (IND) application is currently known to be active for CJC-1295.

The peptide has circulated in the US primarily through 503A compounding pharmacies, which historically prepared patient-specific prescriptions containing CJC-1295 (often marketed as "CJC-1295 without DAC" or "Mod GRF 1-29"). Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare unapproved drug products using bulk drug substances if specific conditions are met, including a valid patient-specific prescription and compliance with USP standards 2.

The FDA has progressively tightened oversight of compounded peptides. In late 2023 and into 2024, the agency issued warning letters to multiple compounding pharmacies selling peptide products, including growth hormone secretagogues. CJC-1295 is not listed on the FDA's published "bulks list" of nominated substances evaluated for use under Section 503B (outsourcing facilities), placing it in a regulatory gray zone where enforcement discretion determines availability 2.

Patients who obtained CJC-1295 through compounding pharmacies should understand that these products carried no FDA review of safety, efficacy, or manufacturing consistency. The FDA's page on compounding risks notes that compounded drugs "are not FDA-approved" and "may have significant quality issues."

European Medicines Agency and EU Member States

The European Medicines Agency (EMA) has never evaluated CJC-1295 through its centralized marketing authorization procedure. No European Public Assessment Report (EPAR) exists for this peptide. ConjuChem did not submit a Marketing Authorization Application (MAA) to the EMA or to any EU national competent authority before discontinuing development.

Within the European Union, CJC-1295 falls under the classification of an unauthorized medicinal product. Individual member states regulate unauthorized medicines through their national pharmaceutical laws. In the United Kingdom (post-Brexit), the Medicines and Healthcare products Regulatory Agency (MHRA) similarly has no record of CJC-1295 authorization. Possession for personal use is not uniformly criminalized across EU member states, but sale and distribution as a medicine without authorization violates EU Directive 2001/83/EC 3.

Online vendors based outside the EU frequently ship CJC-1295 labeled "for research purposes only" into European countries. These products bypass pharmaceutical quality standards entirely. The EMA and national agencies have flagged the broader category of unregulated peptides sold online as a public health concern.

Australia (TGA) and New Zealand (Medsafe)

Australia's Therapeutic Goods Administration (TGA) has not approved CJC-1295. The peptide does not appear on the Australian Register of Therapeutic Goods (ARTG). Under Australia's scheduling framework, CJC-1295 would be classified as a Schedule 4 (prescription-only) substance at minimum if it were ever registered, but since it holds no registration, any importation for human use requires specific authorization under the Special Access Scheme or Authorized Prescriber pathway 4.

The TGA has actively pursued enforcement against suppliers of unapproved peptide products, including growth hormone secretagogues. Australia's border force routinely seizes peptide shipments lacking TGA approval.

New Zealand's Medsafe operates under a similar framework. CJC-1295 is not approved, and importation without authorization constitutes an offense under the Medicines Act 1981.

Canada (Health Canada)

Health Canada has not issued a Drug Identification Number (DIN) or Notice of Compliance (NOC) for CJC-1295. Despite ConjuChem being a Montreal-based company, the peptide never progressed far enough in clinical development to receive Canadian marketing authorization.

Compounding in Canada is regulated at the provincial level, and some compounding pharmacies have historically prepared CJC-1295 formulations. Health Canada's enforcement posture toward compounded peptides has intensified in parallel with the FDA's actions, though the regulatory framework differs. Compounded products in Canada are expected to be prepared in response to a practitioner's prescription for an individual patient 5.

Anti-Doping Classification: WADA and Sports Bodies

The World Anti-Doping Agency (WADA) classifies CJC-1295 as a prohibited substance under Category S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. This prohibition applies at all times, both in-competition and out-of-competition. Any athlete subject to WADA-code testing who tests positive for CJC-1295 faces sanctions including multi-year bans 6.

WADA's prohibition applies regardless of whether the substance is approved or unapproved by any regulatory authority. GH secretagogues as a class, including GHRP-2, GHRP-6, ipamorelin, and CJC-1295, are all explicitly named on the prohibited list. Detection methods for CJC-1295 and its metabolites have been published in anti-doping literature, and modern liquid chromatography-mass spectrometry (LC-MS/MS) assays can identify the peptide in urine samples for several days after administration.

The Only Published Controlled Trial: Teichman et al. 2006

The single published Phase II trial of CJC-1295 (with DAC) remains the primary clinical reference point. Teichman et al. enrolled 21 healthy men in a randomized, double-blind, placebo-controlled ascending-dose study. Subjects received single subcutaneous injections of 30, 60, or 90 mcg/kg 1.

Key findings from this trial:

• Mean GH levels increased 2- to 10-fold over baseline across dose groups, with elevations persisting for up to 6 days after a single injection.
• IGF-1 levels rose 1.5- to 3-fold, peaking between days 2 and 3 and remaining elevated through day 8-11.
• The most common adverse events were injection site reactions (erythema, induration) and transient flushing.
• No serious adverse events were reported within this small, short-duration study.

The trial demonstrated proof of concept for sustained GH-axis stimulation but enrolled too few subjects to establish a safety profile adequate for regulatory submission. Dr. Sam Teichman and colleagues noted that "the prolonged pharmacodynamic effect suggests potential for once-weekly dosing," but acknowledged that larger and longer trials would be necessary 1.

Safety Concerns and the Absence of Post-Market Data

CJC-1295's safety profile is poorly characterized because no large-scale or long-term trials were completed. The death reported during the clinical development program raised concerns that were never resolved through further investigation in a controlled setting.

Known pharmacological risks associated with sustained GH-axis stimulation include:

• Fluid retention and peripheral edema
• Carpal tunnel syndrome
• Arthralgias and myalgias
• Insulin resistance and glucose intolerance
• Theoretical risk of stimulating growth in occult neoplasms

These risks are well-documented for approved GH-releasing agents and exogenous growth hormone itself. The Endocrine Society's clinical practice guidelines on GH use in adults emphasize the importance of monitoring IGF-1 levels and metabolic parameters during GH-axis stimulation therapy 7.

Without post-market surveillance data, pharmacovigilance databases such as the FDA Adverse Event Reporting System (FAERS) contain minimal structured safety data on CJC-1295. Reports that do exist are largely from self-administered products of unknown purity and potency, making causal inference unreliable 8.

CJC-1295 "Without DAC" vs. "With DAC": A Regulatory Distinction That Does Not Exist

Online peptide vendors frequently distinguish between "CJC-1295 with DAC" and "CJC-1295 without DAC" (also called Mod GRF 1-29 or tesamorelin precursor). This distinction carries no regulatory significance. Neither form has been approved by any regulatory authority. The "without DAC" variant is essentially a modified fragment of GHRH (residues 1-29 with amino acid substitutions at positions 2, 8, 15, and 27 to resist enzymatic degradation) and has a half-life of approximately 30 minutes.

Both variants are unapproved investigational compounds. Vendors who market one as "safer" or "more legal" than the other are making claims without regulatory basis. The only FDA-approved GHRH analog is tesamorelin (Egrifta), which is approved specifically for HIV-associated lipodystrophy and carries its own prescribing information and black-box considerations 9.

What Patients Should Know Before Considering CJC-1295

Any use of CJC-1295 in 2026 occurs entirely outside the framework of regulatory approval. Patients who encounter this peptide through anti-aging clinics, wellness centers, or online sources should be aware of several realities. The product has no standardized formulation, no approved dosing regimen, and no required manufacturing quality standards unless prepared by a registered 503A pharmacy operating under a valid prescription. Products purchased from peptide research chemical vendors have no guarantee of identity, purity, or sterility.

Clinicians who prescribe CJC-1295 do so off-label in the most literal sense: there is no label. This places the full burden of informed consent, adverse event monitoring, and clinical judgment on the prescribing provider. Baseline and periodic IGF-1 monitoring, fasting glucose assessment, and screening for contraindications (active malignancy, diabetic retinopathy) represent minimum clinical diligence based on the Endocrine Society's GH-axis guidelines 7.